Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study

被引:7
|
作者
Kachhawa, Garima [1 ]
Kumar, Krithika V. Senthil [1 ]
Kulshrestha, Vidushi [1 ]
Khadgawat, Rajesh [2 ]
Mahey, Reeta [1 ]
Bhatla, Neerja [1 ]
机构
[1] All India Inst Med Sci, Dept Obstet & Gynaecol, New Delhi, India
[2] All India Inst Med Sci, Dept Endocrinol & Metab, New Delhi, India
关键词
menstrual cycle regulation; myo-inositol and d-chiro-inositol combination; polycystic ovary syndrome; young women; AGE;
D O I
10.1002/ijgo.13971
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To compare the effect of myo-inositol and d-chiro-inositol in combination (MI + DCI) with combined hormonal contraceptive (CHC) on menstrual cycle regulation in young Indian women with polycystic ovary syndrome (PCOS). Methods Seventy young women with PCOS aged 15-24 years with delayed cycles were randomized into two groups and were treated for 6 months with MI + DCI (550 + 150 mg, 3.6:1 ratio) twice a day and CHC (ethinyl estradiol 20 mu g + drospirenone 3 mg) once a day. Results Spontaneous menses resumed in 28 (84.85%) young women on MI + DCI, compared with withdrawal bleeding in 34 (100%) on CHC. The mean cycle length reduced with both MI + DCI (124.54 +/- 8.08 to 57.75 +/- 3.00 days, P < 0.001) and CHC (105.88 +/- 7.96 to 30.53 +/- 2.95 days, P < 0.001). Regular menstrual cycles were established in 9 (27.27%) young women with MI + DCI (P = 0.001) and 30 (88.23%) with CHC (P < 0.001). Three months after stopping the treatment, 24 young women (85.71%) on MI + DCI and 25 (73.53%) on CHC continued to have spontaneous cycles. Anti-Mullerian hormone decreased with both the drugs (P = 0.001), whereas luteinizing hormone (P = 0.001) and testosterone (P = 0.04) decreased with CHC and homeostatic model assessment of insulin resistance (P < 0.001) with MI + DCI. Conclusion Myo-inositol and d-chiro-inositol in combination (3.6:1 ratio) are effective in regularizing menstrual cycles and improving insulin resistance. Trial registration Clinical Trials Registry of India (CTRI/2018/03/012643).
引用
收藏
页码:278 / 284
页数:7
相关论文
共 30 条
  • [1] Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome
    Lete, Inaki
    Martinez, Ainara
    Lasaga, Irene
    Centurion, Eva
    Vesga, Amaia
    GYNECOLOGICAL ENDOCRINOLOGY, 2024, 40 (01)
  • [2] The Rationale of the Myo-Inositol and D-Chiro-Inositol Combined Treatment for Polycystic Ovary Syndrome
    Dinicola, Simona
    Chiu, Tony T. Y.
    Unfer, Vittorio
    Carlomagno, Gianfranco
    Bizzarri, Mariano
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (10): : 1079 - 1092
  • [3] Management of polycystic ovary syndrome among Indian women using myo-inositol and D-chiro-inositol
    Vyas, Lila
    Raiturker, Anagha Pai
    Sud, Shilpi
    Goyyal, Poonam
    Abhyankarv, Mahesh
    Ankar, Santosh Rev
    Silki, Silki
    BIOINFORMATION, 2022, 18 (02) : 103 - 110
  • [4] Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome
    Unfer, Vittorio
    Porcaro, Giuseppina
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (05) : 623 - 631
  • [5] Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome who undergo ICSI
    Llaneza, P.
    Aragon, M.
    Maldonado, V.
    Lorente, J.
    Bravo, M. J.
    Fonolla, J.
    Diaz, M. P.
    Olivares, M.
    Mendoza, N.
    HUMAN REPRODUCTION, 2018, 33 : 436 - 436
  • [6] Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial
    Mendoza, Nicolas
    Paz Diaz-Ropero, Maria
    Aragon, Miguel
    Maldonado, Vicente
    Llaneza, Placido
    Lorente, Juan
    Mendoza-Tesarik, Raquel
    Maldonado-Lobon, Jose
    Olivares, Monica
    Fonolla, Juristo
    GYNECOLOGICAL ENDOCRINOLOGY, 2019, 35 (08) : 695 - 700
  • [7] Metabolic and hormonal effects of a combined Myo-inositol and D-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS)
    Januszewski, Marcin
    Issat, Tadeusz
    Jakimiuk, Alicja A.
    Santor-Zaczynska, Malgorzata
    Jakimiuk, Artur J.
    GINEKOLOGIA POLSKA, 2019, 90 (01) : 7 - 10
  • [8] A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women
    Benelli, Elena
    Del Ghianda, Scilla
    Di Cosmo, Caterina
    Tonacchera, Massimo
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2016, 2016
  • [9] Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model
    Bevilacqua, Arturo
    Dragotto, Jessica
    Giuliani, Alessandro
    Bizzarri, Mariano
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (06) : 9387 - 9398
  • [10] Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome
    Zacche, Martino M.
    Caputo, Luigi
    Filippis, Susanna
    Zacche, Gabrio
    Dindelli, Moreno
    Ferrari, Augusto
    GYNECOLOGICAL ENDOCRINOLOGY, 2009, 25 (08) : 508 - 513